<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01263977</url>
  </required_header>
  <id_info>
    <org_study_id>THEMIS</org_study_id>
    <nct_id>NCT01263977</nct_id>
  </id_info>
  <brief_title>Thermodilution - Controlled Management of Volume Therapy in Septic Shock</brief_title>
  <acronym>THEMIS</acronym>
  <official_title>A Randomized Mono-center Study Looking at the Effect of Thermodilution Controlled Therapy for Volume Optimization on the Duration of Septic Shock in Patients With Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Claudia Spies</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Septic shock and multi-organ failure are among the most frequent causes of death in the ICU.&#xD;
&#xD;
      Patients with septic shock require early implementation of hemodynamic therapy to keep the&#xD;
      duration of shock state and with it microcirculatory disturbances as short as possible. In&#xD;
      the septic shock guidelines by the american association SCCM the diagnosis of volume status&#xD;
      is based on filling pressures, like CVP. Some studies show, that the CVP depends not only on&#xD;
      the intravascular volume, but also on the right ventricular compliance, pulmonary vascular&#xD;
      resistance as well as intrathoracic pressure. The aim of the Study is to evaluate if the&#xD;
      duration of septic shock can be reduced through algorithm driven volume therapy orientated to&#xD;
      thermodilution based volume parameters (GEDI and ELWI)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of septic shock</measure>
    <time_frame>6 months</time_frame>
    <description>septic shock is defined as sepsis with mean arterial pressure (MAP) &lt;65mmHg or systolic arterial pressure (SAP) &lt;90mmHg or the need for vasopressors to support the MAP &gt;/= 65 mmHg or the SAP &gt;/= 90 mmHg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>28 day mortality</measure>
    <time_frame>max 28 Tage</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90 and 180 days mortality</measure>
    <time_frame>max 180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive care mortality</measure>
    <time_frame>max 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of arterial hypoperfusion in the extremity of the thermodilution</measure>
    <time_frame>max. 28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Septic Shock</condition>
  <condition>Volume Status</condition>
  <arm_group>
    <arm_group_label>Thermodilution controlled volume management</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volume management based on parameters: GEDI, ELWI, CI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Volume management based on surviving sepsis campaign</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>volume management based on surviving sepsis campaign guidelines: CVP, Urin output, MAP, ScvO2</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Picco- thermodilution catheter</intervention_name>
    <description>Transpulmonary thermodilution and pulse contour analysis with arterial catheter Arterial access via femoral</description>
    <arm_group_label>Thermodilution controlled volume management</arm_group_label>
    <arm_group_label>Volume management based on surviving sepsis campaign</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent from patient, authorized proxy, carer&#xD;
&#xD;
          -  In women of child bearing age, effective contraceptive use with a known failure rate&#xD;
             of &lt;1 %&#xD;
&#xD;
          -  Clinical verification of infection (≥ 48 hours possible), with at least one criteria&#xD;
             from a - d required:&#xD;
&#xD;
               1. Proof of pathological microorganism in blood, sputum, urine or normally sterile&#xD;
                  body tissues&#xD;
&#xD;
               2. Identifiable focus (e.g. purulent sputum or wound secretion, perforated gut)&#xD;
&#xD;
               3. Identification of granulocytes in normally sterile tissue&#xD;
&#xD;
               4. Clinical suspicion of infection without identification of pathogens or&#xD;
                  micro-organisms (e.g. new pulmonary infiltrates on chest x-ray, treated&#xD;
                  pneumonia, purpura fulminants, necrotizing fasciitis)&#xD;
&#xD;
          -  Confirmation of SIRS (≥ 48 hours possible), with at least 2 criteria from a-d&#xD;
             required:&#xD;
&#xD;
               1. Fever (≥38 °C) or Hypothermia (≤ 36 °C)&#xD;
&#xD;
               2. Tachycardia (≥ 90/min)&#xD;
&#xD;
               3. Tachypnoea (≥ 20/min) or Hyperventilation (PaCO2 ≤ 32 mmHg, ≤ 4,4 kPa) or&#xD;
                  mechanical ventilation&#xD;
&#xD;
               4. Leukocytes (≥ 12,000/μl) or Leucopenia (≤ 4,000/μl) or ≥ 10% immature&#xD;
                  granulocytes&#xD;
&#xD;
          -  Sepsis-induced HYPOTENSION despite adequate volume status (&lt;24h):&#xD;
&#xD;
        Mean arterial pressure (MAP) &lt; 65 mmHg (&lt; 8,7 kPa) or systolic arterial pressure (SAP) &lt; 90&#xD;
        mmHg (&lt; 12 kPa) or the need for vasopressor (Norepinephrine &lt;0.05µg/kg/min) to support the&#xD;
        MAP ≥ 65 mmHg (≥ 8,7 kPa) or the SAP ≥ 90 mmHg ≥ 12 kPa), when one of these criteria has&#xD;
        lasted for 4 hours or longer.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Therapy limited (DNR-Order)&#xD;
&#xD;
          -  Patient moribund&#xD;
&#xD;
          -  Pregnancy (positive pregnancy test in women of child bearing age)&#xD;
&#xD;
          -  Breast feeding women&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  Patients active treatment for congestive heart failure with Ejection fraction &lt; 30%&#xD;
             and/or NYHA Class IV congestive heart failure&#xD;
&#xD;
          -  Severe peripheral Arterial Vascular Occlusion Disease ≥ 2b after Fontaine&#xD;
&#xD;
          -  Patients with Glasgow Coma Score ≤ 8 at the time of admission and prior to the&#xD;
             administration of medications such as sedatives&#xD;
&#xD;
          -  Patients with TNM stage 4 solid tumors, hematologic malignancies with high tumor&#xD;
             burden, CNS tumors (WHO stage 4)&#xD;
&#xD;
          -  Patients who are likely to die within days for diseases or conditions other than&#xD;
             catecholamine-dependent shock&#xD;
&#xD;
          -  Participation in another interventional clinical study within the last 30 days&#xD;
&#xD;
          -  Particular relationship to senior investigator (e.g. staff, relative, colleague)&#xD;
&#xD;
          -  Patients with severe liver dysfunction (Child C)&#xD;
&#xD;
          -  Patients with septic shock within the last 60 days&#xD;
&#xD;
          -  Patients receiving norepinephrine for longer than 48 hours&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudia D Spies, MD, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Dept. of Anesthesiology and Intensive Care Medicine, CCM and CVK, Charité - Universitaetsmedizin Berlin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Sander, MD, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Anesthesiology and Intensive Care Medicine, CCM and CVK, Charité - Universitaetsmedizin Berlin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Anesthesiology and Intensive Care Medicine Campus Charité Mitte and Campus Virchow-Klinikum, Charité - Universitaetsmedizin Berlin</name>
      <address>
        <city>Berlin,</city>
        <state>Berlin</state>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>December 20, 2010</study_first_submitted>
  <study_first_submitted_qc>December 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2010</study_first_posted>
  <last_update_submitted>June 5, 2014</last_update_submitted>
  <last_update_submitted_qc>June 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Claudia Spies</investigator_full_name>
    <investigator_title>Department of Anesthesiology and Intensive Care Medicine CVK/CCM, Charite University, Berlin, Germany</investigator_title>
  </responsible_party>
  <keyword>septic shock</keyword>
  <keyword>goal directed volume therapy</keyword>
  <keyword>outcome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

